2m 2m 2m 2m 2m 2m 2m
ADC Therapeutic N (ADCT)
NYSE
$1.66-$1.51 (-47.63%)
Price as of Jun 03, 2026 6:38 PM EDT- $441.1MMarket Cap
- -11.70%1-Year Change
- BiotechnologyIndustry
ADC Therapeutic N (ADCT)
$1.66-$1.51 (-47.63%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 73.6M +6.16% | 69.3M -0.40% | 69.6M -66.86% | 209.9M +518.89% | |
Cost of Revenue | 5.8M -2.54% | 5.9M +135.23% | 2.5M -44.77% | 4.6M +228.72% | |
Gross Profit | 67.8M +6.98% | 63.3M -5.52% | 67.0M -67.36% | 205.3M +531.32% | |
Sales and Marketing Expense | 43.4M -1.46% | 44.0M -23.40% | 57.5M -16.78% | 69.1M +6.59% | |
Research and Development Expense | -104.0M -5.13% | -109.6M -13.76% | -127.1M -32.34% | -187.9M +18.92% | |
Depreciation and Amortization Expense | 705,000 -47.15% | 1.3M +12.38% | 1.2M N/A | N/A N/A | |
Total Operating Expenses | 202.9M +0.68% | 201.5M -14.46% | 235.5M +227.12% | 72.0M +0.76% | |
Operating Profit | -121.5M -7.01% | -130.7M -21.29% | -166.0M +34.26% | -123.6M -52.76% | |
Interest Income | 8.8M -28.21% | 12.3M +16.43% | 10.5M N/A | N/A N/A | |
Interest Expense | -12,000 -99.98% | -50.2M +8.39% | -46.3M N/A | N/A N/A | |
Interest Income and Expense and Net | 8.8M +123.19% | -37.9M +6.02% | -35.8M N/A | 0 N/A | |
Total Nonoperating Income and Expense | -20.1M -21.09% | -25.5M -13.42% | -29.4M +143.65% | -12.1M -142.40% | |
Income before Taxes | -141.6M -9.30% | -156.1M -20.10% | -195.4M +25.43% | -155.8M -32.27% | |
Income Taxes | 1.0M +511.45% | 166,000 -99.58% | 39.1M +3,333.36% | 1.1M +105.30% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -142.6M -9.64% | -157.8M -34.25% | -240.1M +54.08% | -155.8M -32.27% | |
Net Income from Continuing Operations Applicable to Common | -142.6M -9.64% | -157.8M -34.25% | -240.1M +54.08% | -155.8M -32.27% | |
Basic EPS and Net Income | -1.12 -30.86% | -1.62 -44.90% | -2.94 N/A | N/A N/A | |
Diluted EPS and Net Income | -1.12 -30.86% | -1.62 -44.90% | -2.94 N/A | N/A N/A | |
Basic Weighted Average Shares | 127.1M +30.78% | 97.2M +18.91% | 81.7M +4.55% | 78.2M +1.83% | |
Diluted Weighted Average Shares | 127.1M +30.78% | 97.2M +18.91% | 81.7M +4.55% | 78.2M +1.83% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 261.3M +4.17% | 250.9M -9.95% | 278.6M -14.66% | 326.4M -30.03% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 261.3M +4.17% | 250.9M -9.95% | 278.6M -14.66% | 326.4M -30.03% | |
Total Current Assets | 306.3M -0.34% | 307.4M -8.59% | 336.3M -24.60% | 446.0M -15.07% | |
Accumulated Depreciation | 1.4M -74.04% | 5.3M +24.44% | 4.3M N/A | N/A N/A | |
Property and Plant and Equipment and Net | 0 -100.00% | 5.1M -9.73% | 5.6M +72.40% | 3.3M -19.80% | |
Total Long-Term Assets | 1.2M +4.82% | 1.2M +63.29% | 711,000 -99.14% | 83.2M -10.39% | |
Total Assets | 323.1M +0.36% | 322.0M -9.25% | 354.8M -32.95% | 529.2M -14.37% | |
Income Taxes Payable | 789,000 -58.73% | 1.9M +43.54% | 1.3M N/A | N/A N/A | |
Total Short-Term Debt | 3.0M N/A | N/A N/A | N/A N/A | 12.5M N/A | |
Total Current Liabilities | 70.2M -12.81% | 80.5M +18.91% | 67.7M -31.62% | 99.0M +33.84% | |
Total Long-Term Debt | 112.5M -1.04% | 113.6M +0.80% | 112.7M N/A | N/A N/A | |
Total Long-Term Liabilities | 2.8M +15.50% | 2.4M -72.60% | 8.9M -97.40% | 341.5M -9.65% | |
Total Liabilities | 509.0M -2.98% | 524.6M +4.29% | 503.0M +14.21% | 440.4M -2.53% | |
Retained Earnings | -1.6B +9.55% | -1.5B +11.82% | -1.3B +23.58% | -1.1B +16.85% | |
Total Stockholders Equity | -185.8M -8.29% | -202.6M +36.69% | -148.2M -267.08% | 88.7M -46.58% | |
Total Shares Outstanding | 125.7M +27.20% | 98.9M +20.13% | 82.3M -7.58% | 89.0M +16.06% | |
Cash Flow | |||||
Cash from Operating Activities | -141.2M +14.00% | -123.8M +4.34% | -118.7M -13.24% | -136.8M -41.39% | |
Capital Expenditures | 264,000 -69.55% | 867,000 -73.04% | 3.2M N/A | N/A N/A | |
Cash from Investing Activities | 395,000 +145.56% | -867,000 -73.04% | -3.2M +28.23% | -2.5M -62.42% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 150.9M +55.53% | 97.1M +31.38% | 73.9M +12,557.84% | -593,000 -100.22% | |
Financials Ratio | |||||
Gross Margin | 92.12% +0.77% | 91.41% -5.14% | 96.36% -1.49% | 97.82% +2.01% | |
Operating Margin | -165.19% -12.41% | -188.59% -20.97% | -238.63% +305.17% | -58.90% -92.37% | |
Return on Assets | -44.22% -5.21% | -46.65% -14.11% | -54.31% +99.95% | -27.16% -33.18% | |
Return on Equity | 73.43% -18.39% | 89.97% -88.85% | 806.60% +759.61% | -122.28% +33.33% | |
Revenue Growth | 6.16% +1,642.36% | -0.40% -99.40% | -66.86% -112.89% | 518.89% N/A | |
Current Ratio | 4.37 +14.29% | 3.82 -23.13% | 4.97 +10.26% | 4.51 -36.55% | |
Cash Ratio | 3.72 +19.47% | 3.12 -24.27% | 4.12 +24.80% | 3.30 -47.72% | |
Debt-to-Equity Ratio | -0.62 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.36 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow